Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1321-1331
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1321
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1321
Table 1 BALAD score calculation
| 0 point | 1 point | 2 points | 3 points | |
| Bilirubin (mg/dL) | < 1.0 | 1.0-2.0 | > 2.0 | |
| Albumin (g/dL) | > 3.5 | 2.8-3.5 | < 2.8 | |
| Summation of these 2 points, then classified as A (0-1), B (2-3), C (4) | ||||
| Albumin-Bilirubin | A | B | C | - |
| No. of elevated markers1 | 0 | 1 | 2 | 3 |
| Summation of these 2 points for BALAD score (0-5) | ||||
- Citation: Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, Mara KC, Harmsen WS, Theobald JP, Peters BE, Balsanek JG, Ward MM, Giama NH, Venkatesh SK, Harnois DM, Charlton MR, Yamada H, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol 2018; 24(12): 1321-1331
- URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1321.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1321